Patient Guide: Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 1 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06607692
Status: 🟢 Enrolling Now
Condition: Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET), Adrenal Tumours
Phase: PHASE2

Find a Study Location Near You

This study is available at 1 research site. We'll help you connect with the location that's right for you.

Participating sites include:
  • Boadilla del Monte, Madrid

Loading interactive enrollment tools...

The full interactive experience will load momentarily